Hongbo Pharmaceutical Co., Ltd.

Beijing Jiayuan Law Firm's Legal Opinion on Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd.'s 2025 Annual Shareholders' Meeting

Announcement of Resolutions of the 2025 Annual Shareholders' Meeting

Report from CITIC Securities Co., Ltd. on the Continuous Supervision Training of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. for 2025

Summary Report from CITIC Securities Co., Ltd. on the Continuous Supervision of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd.

Regular On-site Inspection Report from CITIC Securities Co., Ltd. on Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. for 2025

Tracking Report from CITIC Securities Co., Ltd. on Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. for 2025

Announcement on Holding the Online Performance Briefing for 2025

Announcement on the Subscription of Fund Shares and Related Transactions and Completion of Business Registration Changes

Announcement of Resolutions from the 8th Meeting of the 4th Board of Directors

Announcement on the Renewal of the Accounting Firm

2025 Annual Board Work Report

2025 Annual Independent Director Work Report (You Qidong)

2025 Annual Independent Director Work Report (Cheng Li)

2025 Annual Independent Director Work Report (Shao Chunyang)

2025 Annual Environmental, Social, and Governance (ESG) Report

CITIC Securities Co., Ltd. Verification Opinion on the 2025 Annual Internal Control Self-Assessment Report of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd.

2025 Annual Internal Control Audit Report

2025 Annual Internal Control Evaluation Report

Compensation Management System for Directors and Senior Management

Management System for the Departure of Directors and Senior Management

Announcement on Requesting Shareholder Meeting Authorization for the Board to Formulate 2026 Mid-Term Dividend Matters

Announcement on the Provision for Credit Impairment Losses and Asset Impairment Losses for 2025

Announcement on the Reversal of Credit Impairment Losses and Provision for Asset Impairment Losses for the First Quarter of 2026

Verification Opinion of the Board Compensation and Assessment Committee on Invalidating Certain Granted but Unvested Restricted Stocks of the 2024 Restricted Stock Incentive Plan

Announcement on Invalidating Certain Granted but Unvested Restricted Stocks of the 2024 Restricted Stock Incentive Plan

Legal Opinion on the Adjustment of Grant Price, Achievement of First Vesting Conditions, and Related Matters of Invalidated Restricted Stocks for the 2024 Restricted Stock Incentive Plan

Verification Opinion of the Board Compensation and Assessment Committee on the Vesting List for the First Vesting Period of the Initial Grant of the 2024 Restricted Stock Incentive Plan

Announcement on the Achievement of the First Vesting Conditions for the Initial Grant of the 2024 Restricted Stock Incentive Plan

Review Opinion of the Nomination Committee on the Qualifications of Non-Independent Director Candidates

Announcement on Nominating Candidates for Non-Independent Directors of the 4th Board of Directors

Notice from Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. on Holding the 2025 Annual Shareholders' Meeting

Announcement of Resolutions from the 7th Meeting of the 4th Board of Directors

Announcement by Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. on the Company's 2025 Annual Profit Distribution Plan

2026 First Quarter Report

Report by the Board Audit Committee on the Evaluation of the Accounting Firm's Performance in 2025 and the Fulfillment of Supervisory Responsibilities

Special Report on Related Party Fund Occupation for 2025

Summary Table of Non-Operating Fund Occupation and Other Related Fund Transactions for 2025

Special Report on the Independence of Independent Directors by the Board of Directors

2025 Annual Audit Report

2025 Annual Report

2025 Annual Report Summary

Announcement on Adjusting the Grant Price of the 2024 Restricted Stock Incentive Plan

Announcement on Requesting Shareholder Meeting Authorization for the Board to Issue Stocks to Specific Objects via Simplified Procedures

Announcement on the election of employee representative directors for the fourth board of directors

Announcement on Estimated Daily Related Party Transactions for 2026

Announcement on Estimated Comprehensive Credit Line for 2026

Announcement on Using Idle Own Funds for Cash Management

Announcement on Providing Guarantee for Bank Credit to Subsidiary Kaiyuan Hongbo

Announcement of Resolutions of the Sixth Meeting of the Fourth Board of Directors

Announcement on the Change of Sponsor Representative